These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30790581)

  • 41. Pharmacokinetics of Monoclonal Antibody and Antibody Fragments in the Mouse Eye Following Systemic Administration.
    Bussing D; Li Z; Li Y; Chang HP; Chang HY; Guo L; Verma A; Shah DK
    AAPS J; 2021 Nov; 23(6):116. PubMed ID: 34750690
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
    Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
    Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
    Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
    Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
    Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Establishing in vitro-in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach.
    Shah DK; Loganzo F; Haddish-Berhane N; Musto S; Wald HS; Barletta F; Lucas J; Clark T; Hansel S; Betts A
    J Pharmacokinet Pharmacodyn; 2018 Apr; 45(2):339-349. PubMed ID: 29423862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models.
    Jain S; Griffith JI; Porath KA; Rathi S; Le J; Pasa TI; Decker PA; Gupta SK; Hu Z; Carlson BL; Bakken K; Burgenske DM; Feldsien TM; Lefebvre DR; Vaubel RA; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
    Clin Cancer Res; 2024 Aug; 30(15):3287-3297. PubMed ID: 38743766
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation.
    Xiao D; Luo L; Li J; Wang Z; Liu L; Xie F; Feng J; Zhou X
    Bioorg Chem; 2021 Nov; 116():105366. PubMed ID: 34560561
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
    Staudacher AH; Brown MP
    Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological Evaluation of Antibody-Drug Conjugates Produced by Tag-Free Lipoate Ligase A Modification.
    Yamazaki S; Ito K; Aoki T; Arashida N; Watanabe T; Fujii T; Matsuda Y
    Biochemistry; 2024 Mar; 63(5):644-650. PubMed ID: 38350078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors.
    Gibiansky L; Passey C; Voellinger J; Gunawan R; Hanley WD; Gupta M; Winter H
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1358-1370. PubMed ID: 35932175
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys.
    Lu D; Jin JY; Girish S; Agarwal P; Li D; Prabhu S; Dere RC; Saad OM; Nazzal D; Koppada N; Ramanujan S; Ng CM
    Pharm Res; 2015 Jun; 32(6):1907-19. PubMed ID: 25467958
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
    Shah DK; Haddish-Berhane N; Betts A
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents.
    Chooniedass S; Dillon RL; Premsukh A; Hudson PJ; Adams GP; MacDonald GC; Cizeau J
    Molecules; 2016 Dec; 21(12):. PubMed ID: 27999336
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carfilzomib Is Not an Appropriate Payload of Antibody-Drug Conjugates Due to Rapid Inactivation by Lysosomal Enzymes.
    Ma Y; Dela Cruz-Chuh J; Khojasteh SC; Dragovich PS; Pillow TH; Zhang D
    Drug Metab Dispos; 2019 Aug; 47(8):884-889. PubMed ID: 31072822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
    Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
    Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cell killing by antibody-drug conjugates.
    Kovtun YV; Goldmacher VS
    Cancer Lett; 2007 Oct; 255(2):232-40. PubMed ID: 17553616
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
    Burton JK; Bottino D; Secomb TW
    AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.